Eduardo MagalhÃ£es Rego

List of Publications by Year
in descending order

264 papers	6,109 citations	117453 34 h-index	98622 67 g-index
274 all docs	274 docs citations	274 times ranked	7790 citing authors

#	Article	IF	Citations
1	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 2022, 40, 438-452.	1.2	6
2	Immunophenotype of acute lymphoblastic leukemia in minoritiesâ€•analysis from the SEER database. Hematological Oncology, 2022, 40, 106-111.	0.8	3
3	Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 2022, , 1.	1.2	0
4	Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2022, 71, 1909-1921.	2.0	5
5	The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia. Nature Communications, 2022, 13, 1105.	5.8	14
6	Adult acute lymphoblastic leukemia in a resource-constrained setting: outcomes after expansion of genetic evaluation. Hematology, 2022, 27, 396-403.	0.7	5
7	COVID-19 induced follicular lymphoma remission. Hematology, Transfusion and Cell Therapy, 2022, 44, 291-292.	0.1	3
8	Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability. Nature Communications, 2022, 13, 2013.	5.8	22
9	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 2022, 83, 105384.	1.1	1
10	Systematic Review of Available CAR-T Cell Trials around the World. Cancers, 2022, 14, 2667.	1.7	31
11	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 2021, 11, 1675.	1.6	2
12	The Expression of NTAL and Its Protein Interactors Is Associated With Clinical Outcomes in Acute Myeloid Leukemia. Molecular and Cellular Proteomics, 2021, 20, 100091.	2.5	1
13	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 2021, 39, 736-746.	1.2	7
14	Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia. Biomarker Research, 2021, 9, 10.	2.8	5
15	Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy, 2021, 44, 124-124.	0.1	2
16	MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. Cell Death and Disease, 2021, 12, 371.	2.7	5
17	(â€“)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1. Scientific Reports, 2021, 11, 9103.	1.6	22
18	Mutational profile of ZBTB16â€RARAâ€positive acute myeloid leukemia. Cancer Medicine, 2021, 10, 3839-3847.	1.3	9

#	Article	IF	Citations
19	Crosstalk between hnRNP K and SET in ATRAâ€induced differentiation in acute promyelocytic leukemia. FEBS Open Bio, 2021, 11, 2019-2032.	1.0	2
20	The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells. Frontiers in Oncology, 2021, 11, 686445.	1.3	8
21	Philadelphia-positive B-lymphoblastic leukemia in a middle-income country â€“ A real-world multicenter cohort. Leukemia Research, 2021, 110, 106666.	0.4	6
22	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. Leukemia and Lymphoma, 2021, 62, 147-157.	0.6	6
23	Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting. Annals of Hematology, 2021, , 1.	0.8	9
24	Artemisinins induce endoplasmic reticulum stress in acute leukaemia cells in vitro and in vivo. EJHaem, 2021, 2, 818.	0.4	0
25	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	2.8	11
26	Activity of Free and Liposomal Antimony Trioxide in the Acute Promyelocytic Leukemia Cell Line NB4. Anticancer Research, 2021, 41, 6061-6065.	0.5	4
27	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
28	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation. Hematology, Transfusion and Cell Therapy, 2021, 43, S54-S63.	0.1	0
29	Viability of Chimeric Antigen Receptor T Cell Therapy in Latin America. Blood, 2021, 138, 4843-4843.	0.6	2
30	Treatment with the Recombinant SLIT2 Protein Delays AML Leukemogenesis In Vivo. Blood, 2021, 138, 2368-2368.	0.6	0
31	Myeloid Immune Cells CARrying a New Weapon Against Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 784421.	1.8	4
32	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 2020, 38, 733-745.	1.2	13
33	Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates â€“ A multicenter cohort study. Leukemia Research, 2020, 89, 106287.	0.4	12
34	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. Cancers, 2020, 12, 3134.	1.7	7
35	Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. BMC Cancer, 2020, 20, 821.	1.1	2
36	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Advances, 2020, 4, 2339-2350.	2.5	11

#	Article	IF	Citations
37	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, 2020, 10, 10315.	1.6	5
38	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 2020, 5, 5.	7.1	26
39	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood, 2020, 135, 870-875.	0.6	48
40	Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e523-e528.	0.2	4
41	Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clinics, 2020, 75, e1566.	0.6	4
42	Challenges in Diagnosis and Treatment of Systemic Amyloidosis: 10 Years of Experience in a Public Brazilian University Center. Blood, 2020, 136, 6-8.	0.6	1
43	Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country. Blood, 2020, 136, 22-23.	0.6	0
44	Assessing Early Mortality in Intensively-Treated Acute Myeloid Leukemia in a Developing Country: Genetic, Laboratory Findings, and Comorbidities Add Prognostic Information. Blood, 2020, 136, 5-6.	0.6	0
45	Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women. Blood, 2020, 136, 37-38.	0.6	0
46	Telehealth in Hematopoietic Cell Transplantation: Perspective from Patients at a Public Hospital in Brazil. Blood, 2020, 136, 26-26.	0.6	1
47	The emerging story of acute lymphoblastic leukemia among the Latin American population â€“ biological and clinical implications. Blood Reviews, 2019, 33, 98-105.	2.8	38
48	Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia. PLoS ONE, 2019, 14, e0221011.	1.1	3
49	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. Blood, 2019, 134, 951-959.	0.6	21
50	CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. Brazilian Journal of Medical and Biological Research, 2019, 52, e8424.	0.7	2
51	Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort. Leukemia Research, 2019, 83, 106165.	0.4	5
52	The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma. Leukemia and Lymphoma, 2019, 60, 2658-2668.	0.6	4
53	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, 2019, 456, 59-68.	3.2	31
54	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	0.6	393

#	Article	IF	Citations
55	Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia. Medical Oncology, 2019, 36, 3.	1.2	8
56	Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil â€“ Early Deaths Are StillÂaÂProblem. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e116-e122.	0.2	20
57	CCR2 Plays a Protective Role in Rocio Virusâ€“Induced Encephalitis by Promoting Macrophage Infiltration Into the Brain. Journal of Infectious Diseases, 2019, 219, 2015-2025.	1.9	8
58	Epigallocatechin-3-Gallate Induces Cellular Differentiation and Reduces Leukemia Burden in PML/RarÎ± Mice By Increasing Reactive Oxygen Species and Reducing PIN1 Expression. Blood, 2019, 134, 5765-5765.	0.6	0
59	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. Blood, 2019, 134, 1682-1682.	0.6	1
60	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 2719-2719.	0.6	0
61	Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells. Blood, 2019, 134, 5165-5165.	0.6	0
62	IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia. Blood, 2019, 134, 2689-2689.	0.6	0
63	MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors. Blood, 2019, 134, 1403-1403.	0.6	0
64	Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model. Blood, 2019, 134, 2977-2977.	0.6	0
65	Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts. Blood, 2019, 134, 2602-2602.	0.6	0
66	Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America. Blood, 2019, 134, 5284-5284.	0.6	0
67	Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults. Blood, 2019, 134, 1354-1354.	0.6	0
68	Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome. Blood, 2019, 134, 4257-4257.	0.6	0
69	Outcomes of HIV-Associated Burkitt Lymphoma in Brazil: High Treatment Toxicity and Refractoriness Rates - a Multicenter Cohort Study. Blood, 2019, 134, 1616-1616.	0.6	0
70	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	0.6	0
71	A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment. Blood, 2019, 134, 4650-4650.	0.6	0
72	Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death and Disease, 2018, 9, 311.	2.7	14

#	Article	IF	Citations
73	Characterization of Conserved and Novel Septal Factors in Mycobacterium smegmatis. Journal of Bacteriology, 2018, 200, .	1.0	42
74	APL in Developing Countries: A Chemotherapy-Based Approach. , 2018, , 211-216.		0
75	The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. British Journal of Haematology, 2018, 180, 915-918.	1.2	2
76	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia and Lymphoma, 2018, 59, 1268-1270.	0.6	1
77	Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. Cancer Letters, 2018, 414, 116-126.	3.2	19
78	GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death. Investigational New Drugs, 2018, 36, 955-960.	1.2	9
79	Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. ELife, 2018, 7, .	2.8	108
80	WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil. Blood, 2018, 132, 5288-5288.	0.6	0
81	Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos â€" a Report from a Large Single Institution Cohort in Southern California. Blood, 2018, 132, 2816-2816.	0.6	0
82	Acute Lymphocytic Leukemia in the Latin American Population. Blood, 2018, 132, 5282-5282.	0.6	2
83	Autophagy Inhibition Potentiates Ruxolitinib-Induced Apoptosis in JAK2V617F Cells. Blood, 2018, 132, 1788-1788.	0.6	0
84	Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment. Blood, 2018, 132, 4760-4760.	0.6	1
85	C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells. Blood, 2018, 132, 3721-3721.	0.6	1
86	Clinical Impact and Therapeutic Opportunity of Insulin Receptor Substrates 1/2 in Acute Myeloid Leukemia. Blood, 2018, 132, 1512-1512.	0.6	0
87	Improving the Outcomes of Acute Promyelocytic Leukemia in a Limited Resources Setting: The Benefit of Early ATRA Administration in 30-Day Survival. Blood, 2018, 132, 5874-5874.	0.6	1
88	NSD1 and NSD2 Transcriptional Levels Might Predict Clinical Outcome in AML Patients. Blood, 2018, 132, 5257-5257.	0.6	2
89	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0
90	KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells. Blood, 2018, 132, 3838-3838.	0.6	0

#	Article	IF	Citations
91	Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. Blood, 2018, 132, 1532-1532.	0.6	0
92	Abnormal Distribution and Function of NK Cells Subsets May Lead to Impaired Tumor Surveillance in a JAK2V617F Myeloproliferative Neoplasm Model. Blood, 2018, 132, 4335-4335.	0.6	0
93	Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America. Journal of Cancer Education, 2017, 32, 845-849.	0.6	3
94	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. Journal of Clinical Pathology, 2017, 70, 435-442.	1.0	19
95	Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia. Haematologica, 2017, 102, e43-e46.	1.7	5
96	Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience. British Journal of Haematology, 2017, 177, 979-983.	1.2	9
97	Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 46-51.	0.7	0
98	IRS1/Î²â€Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells. Journal of Cellular Biochemistry, 2017, 118, 1774-1781.	1.2	17
99	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. Heliyon, 2017, 3, e00405.	1.4	9
100	Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia. Environmental and Molecular Mutagenesis, 2017, 58, 654-661.	0.9	11
101	Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 237-243.	0.7	3
102	Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience. Leukemia Research, 2017, 60, 109-114.	0.4	17
103	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 379-384.	0.7	1
104	Targeting the mitochondria in acute myeloid leukemia. Applied Cancer Research, 2017, 37, .	1.0	12
105	Impact of the ICAL on the treatment of acute leukemia. Blood Advances, 2017, 1, 516-516.	2.5	3
106	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. Blood Advances, 2017, 1, 1807-1814.	2.5	8
107	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. Blood Advances, 2017, 1, 86-89.	2.5	0
108	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. Blood Advances, 2017, 1, 80-83.	2.5	0

#	Article	IF	Citations
109	35 years of the Brazilian Journal of Medical and Biological Research. Brazilian Journal of Medical and Biological Research, 2017, 50, e6153.	0.7	0
110	Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A. Brazilian Journal of Medical and Biological Research, 2017, 50, e6019.	0.7	5
111	Biological X-ray irradiator characterization for use with small animals and cells. Brazilian Journal of Medical and Biological Research, 2017, 50, e5848.	0.7	10
112	Î”Np73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget, 2017, 8, 8475-8483.	0.8	3
113	Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation. Annals of Oncology, 2016, 27, vi304.	0.6	0
114	Reversine triggers mitotic catastrophe and apoptosis in K562 cells. Leukemia Research, 2016, 48, 26-31.	0.4	14
115	Guidelines on the treatment of acute myeloid leukemia: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 58-74.	0.7	4
116	Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice. Cancer Immunology Research, 2016, 4, 312-322.	1.6	45
117	Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia. Tumor Biology, 2016, 37, 9473-9481.	0.8	24
118	Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation.. Journal of Clinical Oncology, 2016, 34, e17061-e17061.	0.8	0
119	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. Blood, 2016, 128, 1886-1886.	0.6	0
120	ROS Production Triggers Anti-Leukemic Effects of Green Tea. Blood, 2016, 128, 5219-5219.	0.6	0
121	Pharmacological IGF1R/IRS Inhibitor, NT157, Effectively Induces Apoptosis and CDKN1A Expression in Acute Lymphoblastic Leukemia Cells. Blood, 2016, 128, 3971-3971.	0.6	0
122	Multitarget Antileukemic Effects of Metformin in Myeloproliferative Neoplasm Cells: Inhibition of JAK2/STAT Signaling and Mitochondrial Activity. Blood, 2016, 128, 1960-1960.	0.6	0
123	Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Family Members Expression in Acute Myeloid Leukemia. Blood, 2016, 128, 5097-5097.	0.6	0
124	Potential roles of micro<scp>RNA</scp>â€29a in the molecular pathophysiology of Tâ€cell acute lymphoblastic leukemia. Cancer Science, 2015, 106, 1264-1277.	1.7	41
125	High Î”Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood, 2015, 126, 2302-2306.	0.6	28
126	Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. Journal of Experimental and Clinical Cancer Research, 2015, 34, 65.	3.5	15

#	Article	IF	Citations
127	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 2015, 26, 2155-2161.	0.6	63
128	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, 2015, 94, 1347-1356.	0.8	31
129	Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nature Medicine, 2015, 21, 457-466.	15.2	220
130	Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells, Molecules, and Diseases, 2015, 54, 97-102.	0.6	29
131	Decreased Activity of NK Cells in Myeloproliferative Neoplasms. Blood, 2015, 126, 1637-1637.	0.6	3
132	Tissue Factor Pathway Inhibitor (TFPI) May be Another Important Factor in the Coagulopathy in Acute Promyelocytic Leukemia (APL). Blood, 2015, 126, 2278-2278.	0.6	4
133	The Use of Cyclosporine in Association with Chemotherapy As Induction Treatment in Patients with Acute Myeloid Leukemia (AML) and High Rhodamine Efflux at Diagnosis Results in Higher Complete Hematological Remission Rates, but Does Not Prolong Overall Survival. Blood, 2015, 126, 4896-4896.	0.6	1
134	Acute Promyelocytic Leukemia. , 2015, , 1-4.		4
135	Acute Promyelocytic Leukemia. , 2015, , 51-54.		448
136	Effect of tumor-associated macrophages on neoplastic progression in sepsis-surviving mice through CXCL12/CXCR4.. Journal of Clinical Oncology, 2015, 33, e22107-e22107.	0.8	0
137	Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells. Blood, 2015, 126, 2772-2772.	0.6	0
138	Association of Setmar Expression with Clinical Characteristics in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 4815-4815.	0.6	1
139	Telomere Dynamics in Monoclonal B-Cell Lymphocytosis and Binet a Chronic Lymphocytic Leukemia. Blood, 2015, 126, 5266-5266.	0.6	0
140	Prognostic impact of <scp>KMT</scp>2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with allâ€trans retinoic acid and anthracyclineâ€based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. British Journal of Haematology, 2014, 166, 540-549.	1.2	13
141	HIGH GRADE GLIOMAS AND DIPG. Neuro-Oncology, 2014, 16, i40-i59.	0.6	1
142	Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: AssociaÃ§Ã£o MÃ©dica Brasileira - 2013. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 71-89.	0.7	18
143	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Annals of Hematology, 2014, 93, 2001-2010.	0.8	58
144	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. Journal of Clinical Oncology, 2014, 32, 9641-9641.	0.8	0

#	Article	IF	Citations
145	Comparison of angiopoietin-1 and -2 and VEGF expression in bone marrow and peripheral blood leukemic cells of patients with acute promyelocytic leukemia.. Journal of Clinical Oncology, 2014, 32, 7079-7079.	0.8	0
146	Early Hematopoietic Progenitors of Dkc1 Hypomorphic Mutant Mice Display Decreased Proliferation Rate and an Impaired Control of Serine/Arginine-Rich Splicing Factor 4 (Srsf4) Translation. Blood, 2014, 124, 2937-2937.	0.6	6
147	Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study. Blood, 2014, 124, 5979-5979.	0.6	0
148	Feasibility of Implementing Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Patients Treated in Developing Countries. Blood, 2014, 124, 5354-5354.	0.6	0
149	LAT2, a Lipid Raft Protein That Participates in AKT Phosphorylation in Mantle Cell Lymphoma, Is a Target for Perifosine Chemotherapy. Blood, 2014, 124, 923-923.	0.6	0
150	Disrupting membrane raft domains by alkylphospholipids. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1384-1389.	1.4	26
151	Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Experimental Hematology and Oncology, 2013, 2, 10.	2.0	49
152	Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Experimental Hematology, 2013, 41, 198-208.	0.2	22
153	FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities. Medical Oncology, 2013, 30, 483.	1.2	3
154	Inhibition of NF-Î²B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and Î³-Radiation Cytotoxicity in Glioblastoma Cells. Chemotherapy Research and Practice, 2013, 2013, 1-16.	1.6	24
155	Genetic Mutations in Patients with Acute Myeloid Leukemia and Leukostasis. Acta Haematologica, 2013, 130, 95-97.	0.7	5
156	Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. British Journal of Cancer, 2013, 109, 2819-2828.	2.9	23
157	Importance of attaining good acute promyelocytic leukemia outcome in developing countries: the IC-APL experience. International Journal of Hematologic Oncology, 2013, 2, 269-271.	0.7	1
158	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013, 121, 1935-1943.	0.6	96
159	The results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countries. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 1-2.	0.7	2
160	TLR9 Priming Promotes Proliferation Of Mesenchymal Stem Cells and Restores The Immunosuppressive Activity Impaired By TLR4 Priming: Potential Involvement Of Non-Canonical NF-Kb Signaling. Blood, 2013, 122, 2458-2458.	0.6	2
161	Thrombin Generationand Fibrinolytic Activity in Microparticles In Acute Promyelocytic Leukemia. Blood, 2013, 122, 3620-3620.	0.6	6
162	Characterization Of Leukemic Stem Cells In AML Cell Lines Using ALDH Staining. Blood, 2013, 122, 5409-5409.	0.6	5

#	Article	IF	Citations
163	The Transcripts Of Platelet-Endothelial Adhesion Molecules and Inflamatory Chemokine Activation Pathway Molecules Are Hyperexpressed In The Bone Marrow Of Acute Promyelocytic Leukemia Patients Presenting Severe Coagulopathy. Blood, 2013, 122, 2574-2574.	0.6	0
164	Telomere Length In Acute Promyelocytic Leukemia. Blood, 2013, 122, 1348-1348.	0.6	0
165	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2013, 122, 2586-2586.	0.6	0
166	Profiling Three-Dimensional Nuclear Telomeric Architecture of Myelodysplastic Syndromes and Acute Myeloid Leukemia Defines Patient Subgroups. Clinical Cancer Research, 2012, 18, 3293-3304.	3.2	40
167	Linker for Activation of T-cell Family Member2 (LAT2) a Lipid Raft Adaptor Protein for AKT Signaling, Is an Early Mediator of Alkylphospholipid Anti-leukemic Activity. Molecular and Cellular Proteomics, 2012, 11, 1898-1912.	2.5	24
168	The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Hematology, 2012, 17, s36-s38.	0.7	5
169	Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. Blood, 2012, 120, 207-213.	0.6	20
170	977 Dehydroxymethylepoxyquinomicin, a Novel Inhibitor of NF-kB Efficiently Suppresses Invasion and Radiosensitizes Glioblastoma Cells. European Journal of Cancer, 2012, 48, S235.	1.3	0
171	Acute promyelocytic leukemia associated with the PLZF-RARA fusion gene: two additional cases with clinical and laboratorial peculiar presentations. Medical Oncology, 2012, 29, 2345-2347.	1.2	17
172	(+)Î±-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia, 2012, 26, 451-460.	3.3	60
173	Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 134-139.	0.7	7
174	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progressionâ€free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63
175	Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia. Medical Oncology, 2012, 29, 1114-1118.	1.2	1
176	Comparative analysis of the pathological events involved in immune and nonâ€immune TRALI models. Vox Sanguinis, 2012, 103, 309-321.	0.7	6
177	Cardiac stunning as a manifestation of ATRA differentiation syndrome in acute promyelocytic leukemia. Medical Oncology, 2012, 29, 248-250.	1.2	20
178	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2012, 120, 1407-1407.	0.6	0
179	Genome-Wide Methylation Analysis of Myeloid Progenitors in Normal Bone Marrow and in Acute Promyelocytic Leukemia At Diagnosis and in Hematological Remission. Blood, 2012, 120, 4611-4611.	0.6	0
180	Generation of Functional Regulatory T Cells From Umbilical Cord Blood Naiˆve T Cells: Potential Role of Hydroxymethylation in the Epigenetic Reprograming and Transcriptional Induction of FoxP3. Blood, 2012, 120, 4835-4835.	0.6	0

#	Article	IF	Citations
181	Halofuginone Has Anti-Proliferative Effects in Acute Promyelocytic Leukemia by Modulating the Transforming Growth Factor Beta Signaling Pathway. PLoS ONE, 2011, 6, e26713.	1.1	34
182	Analysis of five polymorphic DNA markers for indirect genetic diagnosis of haemophilia A in the Brazilian population. Haemophilia, 2011, 17, e936-43.	1.0	8
183	A 23-year-old woman with 11q-chronic lymphocytic leukemia. Medical Oncology, 2011, 28, 1534-1536.	1.2	1
184	Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. Journal of Clinical Apheresis, 2011, 26, 181-185.	0.7	42
185	High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leukemia Research, 2011, 35, 260-264.	0.4	58
186	Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies. Leukemia Research, 2011, 35, 657-662.	0.4	16
187	The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica, 2011, 96, 617-620.	1.7	13
188	EPIDEMIOLOGY AND TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN LATIN AMERICA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011049.	0.5	25
189	DIFFERENTIATION SYNDROME IN PROMYELOCYTIC LEUKEMIA : CLINICAL PRESENTATION, PATHOGENESIS AND TREATMENT. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011048.	0.5	30
190	High Mir-221 Expression Is Associated with Poorer Treatment Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia. Blood, 2011, 118, 1439-1439.	0.6	1
191	Microparticles in Acute Promyelocytic Leukemia,. Blood, 2011, 118, 3346-3346.	0.6	2
192	The Recognition of N-Glycans by the Lectin ArtinM Mediates Cell Death of a Human Myeloid Leukemia Cell Line. PLoS ONE, 2011, 6, e27892.	1.1	27
193	The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 176-177.	0.7	3
194	Acute Promyelocytic Leukemia. , 2011, , 32-35.		0
195	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. Blood, 2011, 118, 3552-3552.	0.6	0
196	Î”Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. Blood, 2011, 118, 3536-3536.	0.6	0
197	Treatment Outcome of Brazilian Patients with Acute Myeloid Leukemia According to the New European LeukemiaNet Recommendations. Blood, 2011, 118, 3146-3146.	0.6	2
198	Flow Cytometry Quantification of Leukemic Stem Cells Is Associated with Risk Stratification and May Be Useful for Minimal Residual Disease in Acute Myeloid Leukemia. Blood, 2011, 118, 1470-1470.	0.6	0

#	Article	IF	Citations
199	Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia. Annals of Hematology, 2010, 89, 225-228.	0.8	11
200	Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil. Medical Oncology, 2010, 27, 1254-1259.	1.2	24
201	Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. Cancer Genetics and Cytogenetics, 2010, 198, 62-65.	1.0	5
202	Tetrasomy 8 in a patient with chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2010, 198, 166-169.	1.0	2
203	The role of micro-ribonucleic acids in normal hematopoiesis and leukemic T-lymphogenesis. Brazilian Journal of Medical and Biological Research, 2010, 43, 619-626.	0.7	7
204	Granulocytic sarcoma of the stomach: Relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 94-98.	0.6	5
205	Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia. Seminars in Thrombosis and Hemostasis, 2010, 36, 917-924.	1.5	49
206	Targeting the Acute Myeloid Leukemia Stem Cells. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 104-110.	0.9	14
207	Interaction of 10-(octyloxy) decyl-2-(trimethylammonium) ethyl phosphate with mimetic membranes and cytotoxic effect on leukemic cells. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1714-1723.	1.4	12
208	Adhesion Molecules in Normal Hematopoiesis and Leukemia. , 2010, , 359-373.		0
209	Smudge cells in peripheral blood smears did not differentiate chronic lymphocytic leukemia from other B-cell chronic lymphoprolipherative diseases. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 333-336.	0.7	6
210	Coagulation abnormalities in acute promyelocytic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, .	0.7	3
211	The presence of CD56/CD16 in Tâ€cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. British Journal of Haematology, 2009, 144, 223-229.	1.2	26
212	Monoclonal Bâ€cell lymphocytosis in firstâ€degree relatives of patients with sporadic (nonâ€familial) chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 147, 339-346.	1.2	31
213	Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in Tâ€cell prolymphocytic leukemia. International Journal of Laboratory Hematology, 2009, 31, 453-456.	0.7	12
214	Apoptosis induction by (+)Î±-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. Leukemia Research, 2009, 33, 958-963.	0.4	11
215	Decolouration of Orange II solutions by TiO2 and ZnO active layers screen-printed on ceramic tiles under sunlight irradiation. Applied Catalysis A: General, 2009, 355, 109-114.	2.2	57
216	Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood, 2009, 114, 5415-5425.	0.6	126

#	Article	IF	Citations
217	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. Blood, 2009, 114, 6-6.	0.6	11
218	Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2008, 74B, 163-168.	0.7	67
219	Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature, 2008, 456, 971-975.	13.7	385
220	The expression of Î”NTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity. British Journal of Haematology, 2008, 142, 74-78.	1.2	16
221	Thalidomide + Dexamethasone as Maintenance after Single Autologous Stem Cell Transplantation Improves Progression-Free Survival (PFS) in Advanced Multiple Myeloma. A Prospective Brazilian Randomized Trial. Blood, 2008, 112, 3703-3703.	0.6	5
222	The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. Journal of Leukocyte Biology, 2007, 82, 1340-1343.	1.5	19
223	Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica, 2007, 92, 1615-1622.	1.7	39
224	Flow cytometry characterization of leukemic phase of nasal NK/T-cell lymphoma in tumor biopsies and peripheral blood. Haematologica, 2007, 92, e24-e25.	1.7	23
225	Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica, 2007, 92, 1431-1432.	1.7	131
226	Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis, 2007, 193, 438-444.	0.4	71
227	Blastoid mantle cell lymphoma with t(2;8) (p12;q24). Leukemia and Lymphoma, 2007, 48, 2079-2082.	0.6	7
228	Acute myeloid leukemia (AML-M2) with t(5;11)(q35;q13) and normal expression of cyclin D1. Cancer Genetics and Cytogenetics, 2007, 172, 154-157.	1.0	7
229	Halofuginone Exerts Antiproliferative and Antiangiogenic Actions on Acute Promyelocytic Leukemia Cells through Modulation of the TGFÎ² Pathway.. Blood, 2007, 110, 2850-2850.	0.6	1
230	Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita. Science, 2006, 312, 902-906.	6.0	363
231	Leukemia with distinct phenotypes in transgenic mice expressing PML/RARÎ±, PLZF/RARÎ± or NPM/RARÎ±. Oncogene, 2006, 25, 1974-1979.	2.6	78
232	PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia Research, 2006, 30, 1333-1339.	0.4	31
233	Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration. Hematology American Society of Hematology Education Program, 2006, 2006, 162-168.	0.9	75
234	In vivo analysis of the role of aberrant histone deacetylase recruitment and RARÎ± blockade in the pathogenesis of acute promyelocytic leukemia. Journal of Experimental Medicine, 2006, 203, 821-828.	4.2	42

#	Article	IF	Citations
235	Clinical Features and Outcome of 148 Patients with Acute Promyelocytic Leukemia in Brazil.. Blood, 2006, 108, 3326-3326.	0.6	1
236	Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model. Brazilian Journal of Medical and Biological Research, 2006, 39, 615-620.	0.7	7
237	In Vivo Analysis of the Anti-Leukemic Activity of Alpha-Tocopherol in Acute Promyelocytic Leukemia.. Blood, 2006, 108, 2011-2011.	0.6	0
238	The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance. British Journal of Haematology, 2005, 128, 407-409.	1.2	11
239	The Structure of the Gene for miR-223 in Humans, a MicroRNA Highly Expressed in Hematopoietic Tissues.. Blood, 2005, 106, 4243-4243.	0.6	0
240	Acute Myeloid Leukemia (AML-M2) with a Novel Translocation t(5;11)(q35;q13) and Normal Expression of Cyclin D1.. Blood, 2005, 106, 4538-4538.	0.6	0
241	Granulocyte colony-stimulating factor and leukemogenesis. Mediators of Inflammation, 2004, 13, 145-150.	1.4	9
242	The higher expression of Î± and Î² isoforms of the human glucocorticoid receptor in leukemic B-progenitors compared to normal CD10+ BM cells does not correlate with methylprednisolone-induced apoptosis. Leukemia, 2004, 18, 890-892.	3.3	1
243	Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARÎ±. Oncogene, 2004, 23, 665-678.	2.6	38
244	Intracranial Castlemanâ€™s disease presenting as hypopituitarism. Neuroradiology, 2004, 46, 830-833.	1.1	6
245	Microgranular and t(11;17)/PLZF-RARÎ± variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RARÎ± gene rearrangement. American Journal of Hematology, 2004, 76, 44-51.	2.0	19
246	Histone Deacetylase Inhibitors and Filgrastim Do Not Synergize with ATRA in the Induction of Changes of Acute Promyelocytic Leukemia Cells Adhesive Properties.. Blood, 2004, 104, 2548-2548.	0.6	0
247	Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. Science, 2003, 299, 259-262.	6.0	387
248	TRATAMENTO DAS INFECÃ‡Ã•ES EM PACIENTES COM PANCITOPENIA SECUNDÃRIA A TRATAMENTO CITORREDUTOR. Medicina, 2003, 36, 446.	0.0	0
249	Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders?. Trends in Molecular Medicine, 2002, 8, 396-405.	3.5	51
250	Molecular basis of Acute Myelogenous Leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2002, 24, .	0.7	0
251	Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Seminars in Hematology, 2001, 38, 54-70.	1.8	28
252	Immunophenotype of normal and leukemic bone marrow B-precursors in a Brazilian population. A comparative analysis by quantitative fluorescence cytometry. Brazilian Journal of Medical and Biological Research, 2001, 34, 183-194.	0.7	10

#	Article	IF	Citations
253	Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression. Journal of Experimental Medicine, 2001, 193, 521-530.	4.2	145
254	Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Seminars in Hematology, 2001, 38, 54-70.	1.8	22
255	Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10173-10178.	3.3	193
256	Two Critical Hits for Promyelocytic Leukemia. Molecular Cell, 2000, 6, 1131-1141.	4.5	146
257	CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10+strong and CD10+weak common acute lymphoblastic leukemia. Leukemia Research, 1999, 23, 441-450.	0.4	11
258	Age-related changes of lymphocyte subsets in normal bone marrow biopsies. , 1998, 34, 22-29.		46
259	Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine. , 1998, 58, 340-341.		8
260	Characterization of acute lymphoblastic leukemia subtypes in Brazilian patients. Leukemia Research, 1996, 20, 349-355.	0.4	23
261	Characterization of Myeloid or Lymphoid Acute Leukemia by a Chemiluminescence Assay. Comparison with Immunocytochemistry Using an Antimyeloperoxidase Antibody. Acta Haematologica, 1993, 90, 19-24.	0.7	7
262	Antinociception induced by intracerebroventricular or intrathecal administration of gentamicin in rats. General Pharmacology, 1992, 23, 481-485.	0.7	5
263	Antinociception induced by intraperitoneal injection of gentamicin in rats and mice. Pain, 1990, 41, 365-371.	2.0	30
264	Differentiation syndrome in acute promyelocytic leukemia: pathogenesis and risk factors. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	1